This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Xenetic Biosciences Toekomstige groei
Future criteriumcontroles 1/6
Xenetic Biosciences's earnings are forecast to decline at 37.8% per annum while its annual revenue is expected to grow at 7% per year. EPS is expected to grow by 30.6% per annum.
Belangrijke informatie
-37.8%
Groei van de winst
30.6%
Groei van de winst per aandeel
| Biotechs winstgroei | 35.0% |
| Inkomstengroei | 7.0% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 16 May 2023 |
Recente toekomstige groei-updates
Geen updates
Recent updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2025 | 2 | -17 | N/A | N/A | 1 |
| 12/31/2024 | 2 | -11 | N/A | N/A | 1 |
| 12/31/2023 | 2 | -7 | N/A | N/A | 1 |
| 3/31/2023 | 2 | -6 | -4 | -4 | N/A |
| 12/31/2022 | 2 | -7 | -5 | -5 | N/A |
| 9/30/2022 | 2 | -7 | -6 | -5 | N/A |
| 6/30/2022 | 1 | -7 | -6 | -5 | N/A |
| 3/31/2022 | 1 | -6 | -5 | -5 | N/A |
| 12/31/2021 | 1 | -6 | -5 | -5 | N/A |
| 9/30/2021 | 1 | -5 | -4 | -4 | N/A |
| 6/30/2021 | 1 | -11 | -4 | -4 | N/A |
| 3/31/2021 | 1 | -11 | -5 | -5 | N/A |
| 12/31/2020 | 0 | -11 | -4 | -4 | N/A |
| 9/30/2020 | 0 | -11 | -5 | -5 | N/A |
| 6/30/2020 | 0 | -14 | -6 | -6 | N/A |
| 3/31/2020 | 0 | -14 | -6 | -6 | N/A |
| 12/31/2019 | 0 | -18 | -6 | -6 | N/A |
| 9/30/2019 | N/A | -19 | -6 | -6 | N/A |
| 6/30/2019 | N/A | -10 | -5 | -5 | N/A |
| 3/31/2019 | N/A | -11 | -6 | -6 | N/A |
| 12/31/2018 | N/A | -7 | -6 | -6 | N/A |
| 9/30/2018 | 8 | -1 | -1 | -1 | N/A |
| 6/30/2018 | 8 | -2 | -1 | -1 | N/A |
| 3/31/2018 | 8 | -3 | 0 | 0 | N/A |
| 12/31/2017 | 8 | -4 | 1 | 1 | N/A |
| 9/30/2017 | 3 | -12 | -8 | -8 | N/A |
| 6/30/2017 | 3 | -13 | -7 | -7 | N/A |
| 3/31/2017 | 3 | -58 | -7 | -7 | N/A |
| 12/31/2016 | 3 | -58 | N/A | -9 | N/A |
| 9/30/2016 | N/A | -57 | N/A | -5 | N/A |
| 6/30/2016 | N/A | -60 | N/A | -6 | N/A |
| 3/31/2016 | N/A | -14 | N/A | -5 | N/A |
| 12/31/2015 | N/A | -13 | N/A | -5 | N/A |
| 9/30/2015 | N/A | -13 | N/A | -7 | N/A |
| 6/30/2015 | N/A | -11 | N/A | -8 | N/A |
| 3/31/2015 | N/A | -13 | N/A | -11 | N/A |
| 12/31/2014 | N/A | -14 | N/A | -13 | N/A |
| 9/30/2014 | N/A | -14 | N/A | -12 | N/A |
| 6/30/2014 | N/A | -13 | N/A | -12 | N/A |
| 3/31/2014 | 1 | -11 | N/A | -9 | N/A |
| 12/31/2013 | 1 | -9 | N/A | -6 | N/A |
| 9/30/2013 | 1 | -7 | N/A | -5 | N/A |
| 6/30/2013 | 1 | -6 | N/A | -5 | N/A |
| 3/31/2013 | 0 | -6 | N/A | -5 | N/A |
| 12/31/2012 | 0 | -6 | N/A | -6 | N/A |
| 9/30/2012 | 0 | -6 | N/A | -6 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 3XB0 is forecast to remain unprofitable over the next 3 years.
Winst versus markt: 3XB0 is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: 3XB0 is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: 3XB0's revenue (7% per year) is forecast to grow faster than the German market (4.6% per year).
Hoge groei-inkomsten: 3XB0's revenue (7% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if 3XB0's Return on Equity is forecast to be high in 3 years time